Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Lamotrigine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A known ✓ | Q15858 | 9/20 | 1.00 |
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 1.00 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 1.00 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 1.00 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 1.00 |
| ▸ | SCN10A known ✓ | Q9Y5Y9 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | PTPN11 | Q06124 | 7/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lamotrigine SCHEMBL722975 | 1.00 | SCN9A (1.00) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL29801510 | 1.00 | SCN9A (1.00) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL29360953 | 1.00 | SCN9A (1.00) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL3976546 | 0.98 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL4142403 | 0.98 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL3167376 | 0.98 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL1401495 | 0.98 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL17372723 | 0.98 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL3976541 | 0.95 | SCN9A (0.91) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL6138267 | 0.91 | SCN9A (0.83) | SCN9ACYP2D6MAOAMAPK1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 32858 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146048-A1 | NOVEL BISINDOLYLMALEIMIDE KINASE INHIBITORS | 4M THERAPEUTICS INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-12636289-B2 | Lamotrigine oral liquid suspension and use thereof | OWP Pharmaceuticals, Inc. (US) | 2026-05-26 | — | — | US | claimed |
| CN-122079853-A | N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases | — | 2026-05-26 | — | — | CN | claimed |
| CN-121558452-B | Sample pretreatment method, kit and detection method for anti-epileptic drug detection | Lianying Yuezhi Scientific Instrument (Wuhan) Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | claimed |
| US-12629377-B2 | Lamotrigine oral liquid suspension and use thereof | ROWP IP HOLDING II LLC | 2026-05-19 | — | — | US | claimed |
| CN-122031406-A | Orally disintegrating tablet and preparation method thereof | 海南卫康制药(潜山)有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| WO-1994015607-A1 | APPLICATION OF LAMOTRIGINE IN THE TREATMENT OF PARKINSON'S DISEASE AND PARKINSONIAN SYNDROMES | RHONE-POULENC RORER S.A. (FR) | 1994-07-21 | — | — | WO | claimed |
| WO-1994013296-A1 | APPLICATION OF LAMOTRIGINE IN THE TREATMENT OF NEUROLOGICAL LESIONS RELATED TO TRAUMATIC INJURIES | RHONE-POULENC RORER S.A. (FR) | 1994-06-23 | — | — | WO | claimed |
| WO-1993025207-A1 | USE OF 3,5-DIAMINO-6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZINE ISETHIONATE FOR THE TREATMENT AND PREVENTION OF DEPENDENCE, TOLERANCE AND SENSITIZATION OF DRUGS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-12-23 | — | — | WO | claimed |
| WO-1993016700-A1 | USE OF 3,5-DIAMINO-6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZINE FOR THE TREATMENT OF PAIN AND ×DEMA | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-09-02 | — | — | WO | claimed |
| EP-0522128-A1 | WATER-DISPERSIBLE TABLETS. | WELLCOME FOUND (GB) | 1993-01-13 | — | — | EP | claimed |
| WO-1992013527-A1 | WATER-DISPERSIBLE TABLETS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-08-20 | — | — | WO | claimed |
| EP-0247892-B1 | TRIAZINE SALT | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-04-24 | — | — | EP | claimed |
| EP-0247892-A1 | Triazine salt | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-12-02 | — | — | EP | claimed |
| US-4602017-A | Substituted aromatic compounds | SMITHKLINE BEECHAM CORPORATION(A PENNSYLVANIA CORPORATION) | 1986-07-22 | — | — | US | claimed |
| EP-0021121-A1 | 1,2,4-Triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-01-07 | — | — | EP | claimed |